Updates are available Correction dated 2022-02-14

Article History

Accepted: 5 October 2021

First Online: 13 October 2021

Change Date: 14 February 2022

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s40261-022-01126-w

Declarations

:

: This meta-analysis has been funded by Boehringer Ingelheim Spain. The authors did not receive compensation related to the development of the manuscript.

: Carlos Escobar has received fees for oral presentations and consultancies from Bayer, BMS/Pfizer, Boehringer Ingelheim, and Daiichi Sankyo. Vivencio Barrios has received fees for oral presentations and consultancies from Bayer, BMS/Pfizer, Boehringer Ingelheim, and Daiichi Sankyo. Gregory Y.H. Lip has been a consultant for Bayer/Janssen, BMS/Pfizer, Boehringer Ingelheim, Verseon, and Daiichi-Sankyo and a speaker for BMS/Pfizer, Boehringer Ingelheim, and Daiichi-Sankyo. Alpesh Amin reported serving as a principal investigator or co-principal investigator of clinical trials of NIH/NIAID, NeuroRx Pharma, Pulmotect, Blade Therapeutics, Novartis, Takeda, Humanigen, Eli-Lilly, PTC Therapeutics, OctaPharma, Fulcrum Therapeutics, and Alexion. He has served as a speaker or consultant for BMS, Pfizer, BI, Portola, Sunovion, Mylan, Salix, Alexion, AstraZeneca, Novartis, Nabriva, Paratek, Bayer, Tetraphase, Achogen, LaJolla, Millenium, Ferring, Seres, PeraHealth, HeartRite, Aseptiscope, and Sprightly.

: Not applicable.

: Not applicable.

: Not applicable.

: The datasets and analysis are available from the corresponding author on reasonable request.

: Not applicable.

: All authors have contributed to the study design, result review, manuscript preparation, and final approval of the manuscript.